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ABSTRACT
Background
Rituximab is used in the treatment of CD20
þ B cell lymphomas and other B cell
lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations
with other drugs such as statins that inhibit cholesterol synthesis and show promising
antilymphoma effects. The objective of this study was to evaluate the influence of statins on
rituximab-induced killing of B cell lymphomas.
Methods and Findings
Complement-dependent cytotoxicity (CDC) was assessed by MTT and Alamar blue assays as
well as trypan blue staining, and antibody-dependent cellular cytotoxicity (ADCC) was assessed
by a
51Cr release assay. Statins were found to significantly decrease rituximab-mediated CDC
and ADCC of B cell lymphoma cells. Incubation of B cell lymphoma cells with statins decreased
CD20 immunostaining in flow cytometry studies but did not affect total cellular levels of CD20
as measured with RT-PCR and Western blotting. Similar effects are exerted by other cholesterol-
depleting agents (methyl-b-cyclodextrin and berberine), but not filipin III, indicating that the
presence of plasma membrane cholesterol and not lipid rafts is required for rituximab-
mediated CDC. Immunofluorescence microscopy using double staining with monoclonal
antibodies (mAbs) directed against a conformational epitope and a linear cytoplasmic epitope
revealed that CD20 is present in the plasma membrane in comparable amounts in control and
statin-treated cells. Atomic force microscopy and limited proteolysis indicated that statins,
through cholesterol depletion, induce conformational changes in CD20 that result in impaired
binding of anti-CD20 mAb. An in vivo reduction of cholesterol induced by short-term treatment
of five patients with hypercholesterolemia with atorvastatin resulted in reduced anti-CD20
binding to freshly isolated B cells.
Conclusions
Statins were shown to interfere with both detection of CD20 and antilymphoma activity of
rituximab. These studies have significant clinical implications, as impaired binding of mAbs to
conformational epitopes of CD20 elicited by statins could delay diagnosis, postpone effective
treatment, or impair anti-lymphoma activity of rituximab.
The Editors’ Summary of this article follows the references.
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Rituximab, a chimeric IgG1 monoclonal antibody (mAb)
that binds the CD20 antigen, is approved for ﬁrst-line
treatment of follicular and diffuse large B cell lymphoma in
combination with chemotherapy, and for the treatment of
rheumatoid arthritis [1–3]. Anti-CD20 mAbs have also shown
promising therapeutic activity in other cancer and auto-
immune indications such as chronic lymphocytic leukemia,
Waldenstro ¨m’s macroglobulinemia, systemic lupus erythema-
tosus, and idiopathic thrombocytopenic purpura [3–5].
Although rituximab has revolutionized the treatment of
various forms of B cell lymphomas, virtually all patients
experience a relapse after single-agent treatment [6]. Novel
treatment regimens in which rituximab is combined with
other anticancer agents are therefore studied intensively to
increase antitumor activity. Combination treatments that
beneﬁt from the good safety proﬁle of rituximab are needed
especially for elderly patients who poorly tolerate more
intensive therapies.
One group of therapeutics for potential use in the
combination with rituximab includes competitive inhibitors
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-
CoAR), referred to as statins. Due to their ability to lower
blood cholesterol levels, statins have been commonly used in
elderly patients to prevent and to treat atherosclerosis of the
coronary vessels [7]. HMG-CoAR is the rate-limiting enzyme
of the mevalonate pathway essential for the synthesis of
isoprenoid compounds including cholesterol, dolichol, and
ubiquinone. Isoprenoid prenyl groups (farnesyl- and gera-
nylgeranyl pyrophosphate) are essential for posttranslational
modiﬁcation of numerous cellular proteins, including Ras
and Rho family members [8]. Prenylation of these proteins is
required for correct membrane localization and their
participation in various signaling pathways. By impairing
protein prenylation, statins exert signiﬁcant cytostatic and
cytotoxic effects against many solid tumor cell lines as well as
hematological malignancies [9]. Some of the antitumor effects
of statins might also result from the ability of these drugs to
interfere with the formation of cholesterol-rich microdo-
mains within the plasma membrane, commonly referred to as
lipid rafts [10,11]. Importantly, statins were shown to exert
antilymphoma effects in vitro [12,13] and in vivo [10,14]. A
recent European multicenter case-control study EPILYMPH
revealed that statin use is associated with a reduction in
lymphoma risk in humans [15], although these results are at
odds with studies carried out in Japan [16]. High-dose
simvastatin was safe and tolerable when combined with
chemotherapy in patients with relapsed or refractory
myeloma or lymphoma [17], and several statins are now
undergoing clinical evaluation in patients with various types
of lymphomas. CD20, the target for rituximab, is a non-
glycosylated integral membrane protein that is expressed on
the surface of virtually all normal and malignant B cells. CD20
represents an attractive therapeutic antibody target, as it
does not undergo shedding or internalization and neither a
circulating isoform nor an endogenous ligand exist that
might interfere with antibody binding. The antitumor effects
of rituximab include complement-mediated lysis, antibody-
dependent cellular cytotoxicity (ADCC), induction of apop-
tosis, and potential delayed ‘‘vaccine’’ effects resulting from
the targeting of tumor-derived antigens from damaged tumor
cells to antigen-presenting cells [18,19]. Rituximab has been
shown to redistribute CD20 to lipid rafts, which are liquid-
ordered domains of the plasma membrane composed of lipid
aggregates with increased cholesterol content [20]. Rituxi-
mab-mediated segregation of CD20 into lipid rafts correlates
with complement-mediated lysis of target cells [21,22]. The
integrity of lipid rafts seems to play a crucial role for a CD20-
induced calcium inﬂux and induction of apoptosis [23].
Cholesterol depletion with methyl-b-cyclodextrin (MbCD)
profoundly reduces apoptosis [23] as well as src family kinase-
dependent calcium mobilization [24] induced by rituximab-
mediated crosslinking of CD20. Based on the potential
convergence of lipid-raft–dependent antitumor effects of
rituximab with the lipid-modulating antitumor activity of
statins, we decided to evaluate the inﬂuence of statins on
rituximab-mediated cytotoxicity.
Methods
Cell Culture
The Burkitt’s lymphoma cell lines Raji, Ramos, and Daudi,
obtained from the American Tissue Culture Collection, were
cultured in RPMI 1640 (Sigma Aldrich) supplemented with
10% heat-inactivated FBS, 100 lg/ml streptomycin, and 250
ng/ml amphoterycin B (Gibco Invitrogen). The cells were
cultured at 37 8Ci n5 %C O 2 in a humidiﬁed atmosphere and
passaged approximately every other day.
Leukocyte Isolation from Blood and Bone Marrow
Peripheral blood (15 ml) of ﬁve patients was taken before
(day 0) or 3 d after atorvastatin (80 mg/d) treatment. Bone
marrow (10 ml) of four patients with B lymphoma was
aspirated from the hip to the heparinized tube. Peripheral
blood or bone marrow was diluted twice with PBS (ﬁnal
volume, 20 ml). Next, 3 ml of Histopaque-1077 (Sigma
Aldrich) was pipetted into two conical centrifuge tubes. A
total of 10 ml of diluted peripheral blood or bone marrow
was slowly layered on the top of Histopaque layer (bone
marrow ﬂoated on top of Histopaque layer). Probes were
centrifuged (400g for 15 minutes at 25 8C) without brake. The
white blood cell ring and plasma were isolated and washed
twice with PBS. The leukocyte pellet was resuspeneded in 5
ml of medium (RPMI or OptiMEM) and counted in a Bu ¨rker
chamber using Tu ¨rk dye. Peripheral blood leukocytes were
used for the determination of CD20/CD21 ratio (described
below), and bone marrow cells were used for experiments
with MbCD (as described below for Raji cells) or frozen in
freezing medium (500 ll medium, 500 ll of FBS, and 100 llo f
DMSO) at  80 8C.
The ﬁve patients recruited for the in vivo study had
hypercholesterolemia, but were otherwise healthy volunteers
who were not statin users. Approval for the study was
obtained from the Institutional Review Board of the Medical
University of Warsaw and was conducted according to the
Declaration of Helsinki. Each patient signed a written
informed consent for the procedures.
Reagents
The following statins were used: atorvastatin (Pﬁzer
Pharmaceuticals), cerivastatin (Bayer), mevastatin (ICN Bio-
chemicals), simvastatin and lovastatin (both from Merck,
Sharp & Dohme Research Laboratory), pravastatin (Bristol-
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acid, berberine chloride, ﬁlipin III, and MbCD were pur-
chased from Sigma Aldrich. Farnesyltransferase-277 (FTI-
277) and geranylgeranyltransferase-298 (GGTI-298) were
from Calbiochem. Water-soluble cholesterol was purchased
from ICN Biochemicals. Rituximab, chimeric IgG,1 was
purchased from Roche. Ofatumumab (2F2; HuMax-CD20) is
a fully human IgG1. B1, mouse IgG2a, was purchased from
Coulter.
Cell Viability Assays
An assay with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylte-
trazolium bromide (MTT) reduction was performed as
described [25]. Cells (control or drug-treated), rinsed twice
with PBS, were seeded into a 96-well ﬂat bottom plate in FBS-
free medium (1310
5/well in 50 ll). Rituximab (10 lg/ml) and
human AB serum (10% ﬁnal concentration; as a complement
source) were added to a ﬁnal volume of 100 ll/well. After a 1-
h incubation, MTT solution (5 mg/ml) was added to each well.
A 4-h incubation at 37 8C was stopped by the addition of 100
ll of 20% SDS in a mixture of N,N-dimethylformamide and
distilled water (1:2, v/v). The absorbances of the samples were
measured on a microplate reader (Bio-Rad Model 680 XR) at
570 nm after overnight incubation at 37 8C. Cell viability was
expressed as a relative viability of tumor cells (% of control
cultures incubated with medium only) and was calculated as
follows: relative viability ¼ [(Ae   Ab)/( Ac   Ab)] 3 100, where
Ab is the background absorbance, Ae is the experimental
absorbance, and Ac is the absorbance of untreated controls.
For the trypan blue exclusion test, control and lovastatin
pretreated cells were collected, and viable cells were counted
in a Bu ¨rker chamber using Tu ¨rk dye. The percentage of
treated viable (unstained) cells as compared to viable cells was
determined as a percentage of viability.
Alamar blue (Biosource International) absorbance was
measured on a ﬂuorescent microplate reader (FLUOStar
Optima; BMG Labtech). The change in the color of the
culture medium was monitored by measuring A540 and A620.
This measurement provided an absorbance value indicating
the pretreatment metabolic activity and was used to normal-
ize the post-treatment metabolic activity. Control and
lovastatin-pretreated cells were seeded into 96-well plates,
treated with rituximab (10 lg/ml) in the presence of 10%
human serum (as a complement source). After 1 h, Alamar
blue was added to a ﬁnal dilution of 1:10. The color was
developed after 24 h of incubation. Cell viability was
calculated as the ratio of absorbance of lovastatin-treated
cells to the absorbance of control cells.
For ADCC assays, Raji cells were labeled with 100 lCi
51Cr
(Amersham Biosciences) for 1 h. After extensive washing in
PBS, the cells were adjusted to 1 3 10
5 cells/ml and added to
round-bottom microtiter plates (Greiner Bio-One). Then,
rituximab (0.0005 to 2.5 lg/ml) or a control medium were
added for 15 minutes followed by addition of peripheral
blood mononuclear cells used as effector cells at an effector-
to-target (E:T) cell ratio of 100:1. After incubation (4 h, 37 8C),
assays were stopped by centrifugation, and
51Cr release from
triplicate samples was measured as counts per minute (cpm)
in a scintillation counter. Percentage of cellular cytotoxicity
was calculated using the formula: % speciﬁc lysis ¼
(experimental cpm   basal cpm) / (maximal cpm   basal
cpm) 3 100, where maximal
51Cr release was determined by
adding Triton X-100 (1.5% ﬁnal concentration) to target
cells, and basal release was measured in the absence of
sensitizing antibodies and effector cells.
FACS Analysis
Cells at a density of 1 3 10
6/ml were incubated with
saturating amounts of FITC-conjugated mAb against CD20
(clone B9E9 [HRC20]; Beckman Coulter), and HLA-DR (clone
Immu357; Beckman Coulter ), CD45 RA (clone HI100; Becton
Dickinson) or PE-conjugated mAb against CD19 (clone J4.119;
Beckman Coulter) and CD22 (clone SJ10.1H11; Beckman
Coulter) and FITC- or PE-conjugated IgG1 (isotypic control,
Beckman Coulter; 1:5 dilution) for 30 min at room temper-
ature in the dark. Prior to analysis cells were ﬁxed for 20 min
in OptilLyse C Lysing Solution (Beckman Coulter), washed
twice with PBS, and resuspended in PBS at the density 1 3
10
5. Cells were analyzed on an EPICS/XL-MCL ﬂow cytometer
using System II software version 3.0. For rituximab binding,
Raji, Ramos, or Daudi cells were incubated at room temper-
ature for 30 min. After washing in PBS (three times), cells
were resuspended in 100 ll PBS and stained in the dark for 30
min with polyclonal FITC-conjugated antibody (DAKOCyto-
mation).
Freshly isolated leukocytes of patients with hypercholester-
olemia were stained with FITC-conjugated CD20 mAb
(ofatumumab, or B1) and PE-conjugated CD21 mAb (B-ly4;
BD Pharmingen). Cells were incubated for 30 min at room
temperature in the dark. After washing with FACS buffer,
cells were analyzed on a FACS Calibur (Becton Dickinson)
using Cell Quest Pro software version 5.2. CD20 mAb binding
intensity was identiﬁed by gating on viable cells in the
lymphogate (FSC versus SSC) and CD21
þ cells. The mean
ﬂuorescence intensity (MFI) serves as a measure for mAb
binding on a per-cell basis. The ratio of MFI of CD20/CD21
mAb staining was calculated and served as a measure for
CD20 expression.
Western Blotting
Control cells or cells incubated with 10 lM lovastatin for 48
h were washed twice with PBS, pelleted, and lysed with
radioimmunoprecipitation assay buffer containing Tris base
50 mM, NaCl 150 mM, NP-40 1%, sodium deoxycholate
0.25%, and EDTA 1 mM supplemented with Complete
protease inhibitor cocktail tablets (Roche Diagnostics).
Protein concentration was measured using Bio-Rad Protein
Assay. Equal amounts of whole-cell proteins were separated
on 12.5% SDS-polyacrylamide gel, transferred onto Protran
nitrocellulose membranes (Schleicher and Schuell Bio-
Science), blocked with TBST (Tris-buffered saline [pH 7.4]
and 0.05% Tween 20) supplemented with 5% nonfat milk and
5% FBS. The following mAbs (at 1:1000 dilution) were used
for the overnight incubation: anti-CD20 (NCL-CD20-L26;
Novocastra Laboratories), and anti–ICAM-1 (Santa Cruz
Biotechnology). After extensive washing with TBST, the
membranes were incubated for 45 min with peroxidase-
conjugated ImmunoPure Goat Anti-Mouse IgG [F(ab9)2]
(Jackson ImmunoResearch Laboratories). The chemilumines-
cence reaction for horseradish peroxidase was developed
using the SuperSignal WestPico Trail Kit (Pierce) on a
standard x-ray ﬁlm. The blots were stripped in 0.1 M glycine
(pH 2.6) and reprobed with anti-tubulin mouse mAb
(Calbiochem).
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Cells treated for indicated times with 10 lMl o v a s t a t i n
were washed twice with PBS, pelleted, and treated with 1
ml TRIzol Reagent (Invitrogen) to extract total RNA
according to the manufacturer protocol. RNA concentra-
tion was measured with an Eppendorf Biophotometer. The
ﬁrst-strand cDNA synthesis containing 1 lgt o t a lR N Aw a s
primed with oligo(dT) using Omniscript RT Kit (Qiagen).
Primers used for CD20 PCR ampliﬁcation were forward: 59
TGAATGGGCTCTTCCACATTGCC39 and reverse: 59
CCTGGAAGAAGGCAAAGATCAGC39. The cycling condi-
tions in the Mastercycler personal (Eppendorf) consisted of
aﬁ r s ts t e po f9 48C denaturation for 10 min, followed by 35
cycles of annealing at 54 8Cf o r6 0s ,e x t e n s i o na t7 58Cf o r
90 s, and denaturation at 94 8Cf o r3 0s ,w i t haﬁ n a l
elongation step at 75 8C for 10 min using HotStar Taq DNA
Polymerase (Qiagen). Ampliﬁcation products were ana-
lyzed by 1.5% agarose gel electrophoresis.
Transient siRNA Transfection
At 24 h before transfection, Raji cells were seeded from
single-cell suspension at 2 3 10
5 cells/well in a 24-well plate.
After overnight culture, cells were transfected with siRNA
against HMG-CoAR (sequences provided by Qiagen) using
HiPerFect Transfection Reagent (Qiagen) according to the
manufacturer’s protocol.
Immunofluorescence
Control and lovastatin-pretreated cells were stained in
suspension at a density of 5 3 10
5/ml with anti-CD20 FITC-
conjugated mAb (1:10 in PBS; Immunotech Coulter) for 30
min at room temperature. After washing in PBS (three times),
200 ll of the cell suspension was spun onto a cytospin slide.
The slides were air-dried, acetone-ﬁxed for 15 min at room
temperature, washed 3 times with PBS, and incubated with
anti-CD20 mAb (Novocastra; 1:100 in PBS with 5% normal
donkey serum [Jackson]) for 60 min at room temperature.
The slides were washed three times in PBS and incubated with
donkey anti-mouse Alexa555-conjugated antibody (Molecular
Probes; 1:200 for 30 min at room temperature). The slides
were washed, mounted in Vectashield (Vector Laboratories),
and examined by ﬂuorescence microscopy (Leica TCS SP2).
Surface Protein Biotinylation
Control and lovastatin-treated cells, washed three times
with ice-cold PBS (pH 8.0) and resuspended at a density of 25
3 10
6 cells/ml, were surface-labeled with 2 mM (ﬁnal
concentration) EZ-link sulfo-NHS-biotin (Pierce) for 30 min
at room temperature. Cells were washed three times (in PBS
with 100 mM glycine) and lysed with radioimmunoprecipita-
tion assay lysis buffer containing protease inhibitors (as
described earlier). Next, samples were mixed for 1 h at room
temperature with immobilized NeutrAvidin Protein (Pierce)
to separate the biotinylated surface protein from non-
biotinylated surface protein. After ﬁve washings, gel-bound
complexes were boiled in 23 Laemmli sample buffer and
analyzed for CD20 by Western blotting using anti-CD20 mAb
(Novocastra) as described above.
Atomic Force Microscopy
The measurements were performed using a custom-made
atomic force microscope described in more detail elsewhere
[26]. The device used for the experiment was equipped with a
‘‘liquid cell’’ setup to assure native conditions. Commercially
available silicon nitride cantilevers with the spring constant
of 0.01 N/m (MLCT-AUHW; Veeco Probes) and a nominal tip
radius of about 20 nm were used as probes. All measurements
were performed in PBS buffer at room temperature. Two
types of experiments were performed: (i) control measure-
ments where the antigen-antibody interaction was studied
between rituximab attached to the atomic force microscopy
(AFM) probe and CD20 present on a surface of intact Raji
cells; and (ii) measurements with rituximab attached to the
AFM probe and CD20 present on a surface of Raji cells,
previously incubated for 48 h with 10 lM lovastatin. Force
curves, reﬂecting the relationships between the cantilever
deﬂection and the relative sample position, were recorded at
the constant retraction velocity of 4.6 lm/s. The determined
system spring constant was about 0.00032 N/m. Thus, the
loading rate deﬁned as a product of these two values resulted
in 1,472 piconewton (pN)/s. The total number of the curves
was about 1,500 for each measurement type. The measure-
ments were repeated three times with newly immobilized
antibody and a new sample (Raji cells attached to the poly-L-
lysine–coated glass coverslips). In order to assure that the
force measured by AFM originated from the speciﬁc
interaction between the antibody (rituximab) and its antigen
CD20 present on the cell plasma membrane, the antigens
were blocked during the course of 1-h incubation of
lovastatin-treated cells with PBS buffer containing 10 lg/ml
of the antibody. Next, cells were washed and immediately
measured with AFM using the antibody functionalized AFM
cantilever. The functionalization protocol was described
earlier [27]. Brieﬂy, standard silicon nitride cantilevers were
cleaned in acetone for 15 minutes and then irradiated with
UV light for 30 minutes. After overnight silanization with 3-
aminopropyltriethoxysilane (APTES; Sigma Aldrich) in a
desiccator, cantilevers were immersed in glutaraldehyde
(Fluka) dissolved in PBS (2.5%) for 30 minutes. Afterwards,
they were washed with PBS buffer and functionalized by
sinking in the antibody solution (10 lg/ml) for 1 h.
Digestion of Surface Proteins with Trypsin and
Chymotrypsin
Control and lovastatin-treated Raji cells (2 3 10
6) were
rinsed with PBS, centrifuged under mild conditions (60g for 5
min), and suspended in 100 ll PBS (pH 7.4). Cells were
incubated for 10 min at 37 8C with 0, 0.5, 1.5, 2, and 2.5 lgo f
bovine pancreas trypsin (T; Sigma Aldrich) or chymotrypsin
(ChT; Sigma Aldrich). After enzyme inactivation with 20 lg
soybean trypsin inhibitor (Sigma Aldrich), cells were centri-
fuged (60g for 5 min), lysed by boiling in Laemmli sample
buffer, and subjected to SDS-PAGE. Separated proteins were
transferred to a nitrocellulose membrane and probed with
anti-CD20 (Novocastra) and anti-tubulin (Calbiochem) mAbs.
Statistical Analysis
Data from cytotoxicity experiments were calculated using
Microsoft Excel 98 and represent mean 6 standard deviation.
Differences in cytotoxicity assays were analyzed for signiﬁ-
cance by Student’s t test. Signiﬁcance was deﬁned as a two-
sided p , 0.05. All experiments using cell lines were
performed at least three independent times, the AFM
experiment was performed twice, and the experiments using
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but always in duplicate.
Results
Statins Abrogate Antitumor Activity of Rituximab Against
Raji B Cell Lymphoma Cells
Complement-dependent cytotoxicity (CDC) contributes
signiﬁcantly to the clinical efﬁcacy of rituximab. Therefore,
the potential of rituximab to induce CDC of Raji cells was
assessed in a MTT assay after 1-h incubation in the presence
of human AB serum as a complement source. Incubation of
Raji cells with rituximab (10 lg/mL) and 10% human AB
serum resulted in killing of 60%–80% of lymphoma cells.
Neither rituximab nor AB serum alone affected viability of
tumor cells under these experimental conditions (not shown).
A 48-h preincubation of Raji cells with lovastatin resulted in a
dose-dependent reduction of rituximab-mediated CDC (Fig-
ure 1A). As a control, lovastatin treatment alone did not
affect the viability of Raji cells (unpublished data). The
protection of Raji cells against CDC following preincubation
with lovastatin was observed over a dose range of rituximab
concentrations (0.1–100 lg/ml; Figure 1B). The reduced cell
lysis was conﬁrmed when viability of lymphoma cells
preincubated with 5 lM lovastatin was examined by other
methods, including a trypan blue exclusion assay or a
ﬂuorescent Alamar blue assay (Figure 1C). Because these
results were consistent, we used the MTT assay for evaluating
cell viability in further experiments.
Statins are structurally related, but they have several
unique pharmacodynamic properties that result in pleio-
tropic, presumably HMG-CoAR–independent effects [28].
Therefore, we examined the inﬂuence of other statins on
rituximab-mediated CDC of Raji cells. A 48-h incubation of
Raji cells with all additionally investigated statins (atorvasta-
tin, cerivastatin, ﬂuvastatin, mevastatin, pravastatin, and
simvastatin) conferred resistance to rituximab-mediated
CDC (Figure 1D).
ADCC is another important mechanism involved in
rituximab-mediated cytotoxicity. Control and lovastatin-pre-
treated
51Cr-labelled lymphoma cells were used as targets in
an ADCC reaction with peripheral blood mononuclear cells
as effectors. A 48-h incubation of Raji cells with 10 lM
lovastatin impaired ADCC across a range of rituximab
concentrations (0.0005–2.5 lg/ml; Figure 1E).
Lovastatin Does Not Change the Expression Level of CD20
In addition to lowering of cholesterol synthesis, statins
exert pleiotropic effects, thereby inﬂuencing the expression
of a number of different genes [28–30]. Therefore, we
hypothesized that statin-mediated effects might result from
down-regulating CD20 expression. To evaluate the inﬂuence
of statins on CD20 expression, ﬂow cytometry was performed
using a FITC-conjugated mAb (clone B9E9) that binds to an
extracellular conformational epitope of CD20. These studies
revealed a signiﬁcantly decreased binding of anti-CD20 mAb
to Raji cells incubated with a range of lovastatin concen-
trations (from 1–20 lM). While more than 95% of control
Raji cells stained positive for CD20, only 30% of cells showed
signiﬁcant binding to CD20 after a 48-h pretreatment with 10
lM lovastatin (Figure 2A). Simultaneously, staining for other
B cell markers (CD22, HLA-DR, and CD45RA) in lovastatin-
treated Raji cells did not change, and CD19 staining was only
slightly decreased (Figure 2D–2G). In contrast, we did not
observe reductions of CD20 mRNA levels in time course
(Figure 2B) and dose-titration (unpublished data) experi-
ments with lovastatin-treated Raji cells. Also, a 48-h incuba-
tion with different concentrations of lovastatin (from 5–30
lM) did not inﬂuence the total amount of CD20 protein in
the cells, as determined by Western blotting (Figure 2C).
Decreased binding of CD20 mAb in the absence of the
reduction in CD20 mRNA and protein levels might be
explained by a retention/redistribution of CD20 into cyto-
solic compartments, its shedding from the plasma membrane
or other mechanisms. To examine the subcellular localization
of CD20 in Raji cells, we performed a double immunoﬂuor-
escence staining with anti-CD20 mAb directed against an
extracellular epitope of CD20, and, after cell permeabiliza-
tion, with a mAb against a linear intracellular epitope. While
in untreated controls both mAb detected CD20 expressed on
Raji cells, a 48-h pretreatment with lovastatin nearly
completely abrogated binding of mAb directed to the
extracellular epitope (Figure 2H). However, mAb directed
against the cytosolic tail of CD20 retained its membrane
staining (Figure 2I). These experiments indicate that in
lovastatin-treated cells, CD20 is still present in the plasma
membrane.
To further elucidate these observations, we labeled control
and lovastatin-treated cells with EZ-link sulfo-NHS-biotin.
This water-soluble and membrane impermeable reagent
stably binds to primary amino (-NH2) groups of extracellular
portions of membrane proteins. Labeled cells were lysed and
biotinylated proteins were precipitated with immobilized
NeutrAvidin protein. Electrophoresis of the precipitates
followed by blotting with anti-CD20 mAb (targeting the
cytoplasmic portion of CD20) revealed that CD20 in
lovastatin-treated cells is detectable in comparable, albeit
slightly lower levels as compared with controls (Figure 2J).
The expression of ICAM-1, another transmembrane protein,
was identical in control and lovastatin-treated cells (Figure
2J). Therefore, these studies conﬁrm that CD20 remains in the
plasma membrane of lovastatin-treated cells.
Impaired Rituximab-Mediated CDC in Cholesterol-
Depleted Cells Is Not Dependent on Disruption of Lipid
Rafts
Binding of rituximab to CD20 has been shown to trans-
locate CD20 to cholesterol-rich microdomains within the
plasma membrane; this effect was associated with induction
of apoptosis of lymphoma cells and activation of CDC [22,23].
As statins, by inhibiting cholesterol biosynthesis, have been
shown to interfere with the formation of lipid rafts [11], we
hypothesized that the impaired rituximab-mediated CDC
might result from the inability to translocate CD20 to these
microdomains. To verify this hypothesis, Raji cells were
incubated with MbCD and ﬁlipin III, which disrupt lipid rafts
via different mechanisms: MbCD extracts cholesterol from
the plasma membrane, whereas ﬁlipin III binds stoichio-
metrically to cholesterol, thereby introducing additional
charge that forces cholesterol molecules to distribute evenly
within the plasma membrane [31]. These two reagents
produced completely different effects in our studies. While
MbCD abrogated rituximab-mediated CDC (Figure 3A),
ﬁlipin III had no effect (Figure 3B). Interestingly, berber-
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Statins Impair Antitumor Effects of RituximabFigure 1. Statins Protect Raji Cells Against Rituximab-Mediated CDC
(A) Raji cells were incubated with either diluent or increasing doses of lovastatin (from 1 to 10 lM) for 48 h. Then, equal numbers of cells (1310
5/well)
were incubated for 60 min with 10 lg/ml rituximab in the presence of 10% human AB serum as a complement source. Cell viability was measured in a
MTT assay. The survival of cells is presented as percentage of corresponding diluent- or statin-pretreated cells without rituximab.
(B) Raji cells were incubated with either diluent or lovastatin at 10 lM concentration for 48 h. Then, equal numbers of cells (1310
5/well) were incubated
for 60 min with serial dilutions (from 100 to 0.1 lg/ml) of rituximab in the presence of 10% human AB serum a complement source. Cell viability was
measured in a MTT assay. The survival of cells is presented as percentage of corresponding diluent- or statin-pretreated cells without rituximab.
(C) Raji cells were incubated with either diluent or 5 lM lovastatin for 48 h. Then, equal numbers of cells (1310
5/well) were incubated for 60 min with
10 lg/ml rituximab in the presence of 10% human AB serum as a complement source. Cell viability was measured with MTT assay, Alamar blue assay,
and trypan blue exclusion assay.
(D) Raji cells were incubated with either diluent or simvastatin (10 lM), mevastatin (10 lM), fluvastatin (10 lM), atorvastatin (10 lM), lovastatin (10 lM),
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Statins Impair Antitumor Effects of Rituximabine—an agent that inhibits cholesterol synthesis but in an
HMG-CoAR–independent mechanism [32]—signiﬁcantly de-
creased rituximab-mediated CDC (Figure 3C). Accordingly,
we have also observed that a 30-min incubation with MbCD
(Figure 3D) and a 24-h incubation with berberine (Figure 3F)
but not ﬁlipin III (Figure 3E) impaired binding of anti-CD20
mAb to Raji cells. These results indicate that the presence of
plasma membrane cholesterol and not lipid rafts are critical
for binding of anti-CD20 mAb to lymphoma cells as well as
for rituximab-mediated CDC of lymphoma cells.
Impaired Binding of Anti-CD20 mAb Results from
Inhibition of HMG-CoAR and Is Observed for Type I and
Type II Anti-CD20 mAb
In subsequent studies, we investigated the inﬂuence of
other statins on binding of anti-CD20 mAb to Raji cells.
Incubation of Raji cells with cerivastatin (Figure 4A),
ﬂuvastatin (Figure 4B), and atorvastatin (Figure 4C), as well
as simvastatin and mevastatin (unpublished data), resulted in
analogous effects to lovastatin, indicating that detection of
CD20 and anti-CD20–mediated effector functions are
strongly associated with inhibition of HMG-CoAR. To further
exclude a possibility that the presence of drugs might
interfere with antibody binding, the expression of HMG-
CoAR was silenced with siRNA. Inhibition of HMG-CoAR
expression resulted in a decreased binding of anti-CD20 mAb
to Raji cells (Figure 4D).
Downstream products of HMG-CoAR activity are isopre-
noid compounds that include farnesyl and geranylgeranyl
pyrophosphates used for posttranslational protein modiﬁca-
tion. A 48-h preincubation of Raji cells with inhibitors of FTI
and GGTI did not decrease CD20-mediated CDC (unpub-
lished data), indicating that the effects of statins are
independent from impaired prenylation of intracellular
proteins. As a control, FTI and GGTI alone only modestly
affected the viability of Raji cells.
To study whether our observations were restricted to
rituximab and B9E9, we also tested ofatumumab (a type I
CD20 mAb directed to a distinct CD20 epitope) and the type
II CD20 mAb B1 [33] for CD20 binding and CDC after
cholesterol depletion. Indeed, MbCD treatment also de-
creased CD20 binding of both ofatumumab and B1 to Daudi
cells (Figure 4E) and Raji cells (ofatumumab and rituximab,
;50% reduction; B1 and B9E9, ;80% reduction). However,
MbCD treatment affected ofatumumab-mediated CDC less
severely compared with rituximab, especially for Raji cells
(with 60% versus 82% of cells surviving respectively;
unpublished data).
Importantly, preincubation of Ramos cells with 10 or 50
lM lovastatin for 48 h did not impair alemtuzumab-mediated
CDC (Figure 4F). Alemtuzumab is a mAb approved for
clinical use that binds CD52, which is a GPI-anchored
glycoprotein expressed on the surface of lymphoma cells.
Studies with two additional lymphoma cell lines, Ramos
and Daudi, showed a similar decrease in rituximab and B9E9
binding as compared with that observed with Raji cells
(Figure 5A–5C). The decrease in rituximab binding upon
lovastatin treatment correlated with a decreased efﬁcacy of
CDC (Figure 5A–5C).
Cholesterol Is Necessary for CD20 Binding and Rituximab-
Mediated CDC
To further investigate the role of cholesterol in binding of
anti-CD20 mAb to the target antigen and in rituximab-
mediated CDC, we performed restitution experiments.
Preincubation of Raji cells with 10 lM lovastatin followed
by a 30-min incubation with exogenous cholesterol signiﬁ-
cantly restored or improved binding of anti-CD20 mAb
(Figure 6A). Similarly, a 30-min incubation of Raji cells with
cholesterol after a 48-h pretreatment with 10 lM lovastatin
completely restored sensitivity of lymphoma cells to ritux-
imab-mediated CDC (Figure 6B). Accordingly, co-treatment
of Raji cells with mevalonic acid, a direct product of HMG-
CoAR, completely restored binding of anti-CD20 mAb
(Figure 6C) as well as rituximab-mediated CDC of statin-
treated cells (Figure 5D). Similar results were obtained with
exogenous cholesterol that signiﬁcantly reversed MbCD-
induced effects (Figure 6E and 6F).
Lovastatin Changes Conformation of CD20
Impaired rituximab-mediated CDC as well as impaired
binding of anti-CD20 mAb to Raji cells incubated with 10 lM
lovastatin for 48 h did not seem to result from decreased
expression or shedding of CD20 from plasma membrane.
Rapid (within 30 min) restoration of rituximab-mediated
CDC after the addition of cholesterol indicates that CD20
might undergo cholesterol-dependent conformational
changes. Association of CD20 with the plasma membrane
prevents the use of direct crystallography to study conforma-
tional changes of this molecule. To address this issue, we
therefore performed studies with AFM. Changes of CD20
conformation were furthermore studied by performing
limited proteolysis.
For AFM measurements, rituximab was attached to an AFM
probe, and Raji cells were immobilized onto coverslips. The
binding force of immobilized rituximab to CD20 was assessed
using Raji cells preincubated for 48 h with 10 lM lovastatin.
As a control, the experiment was repeated with diluent-
treated Raji cells and lovastatin-treated cells on which the
available binding sites were blocked with soluble rituximab
(at 10 lg/ml). The unbinding force of a single pair of
molecules can be directly measured by AFM with pN
resolution. Its value is characteristic for the studied inter-
action under the given experimental conditions. A stronger
unbinding force indicates a stronger molecular interaction
and thereby indicates a higher afﬁnity binding of rituximab
to the surface of Raji cells. A typical force curve of an
unbinding event is presented in Figure 7A. Its main
characteristics were similar before and after treatment with
lovastatin. A common method of determining the unbinding
force for a molecular interaction is to attribute the position
cerivastatin (1 lM), or pravastatin (10 lM) for 48 h. Then, equal numbers of cells (1310
5/well) were incubated for 60 min with 10 lg/ml rituximab in the
presence of 10% human AB serum as a complement source. Cell viability was measured with MTT assay.
(E) Raji cells were incubated with either diluent or lovastatin at 10 lM concentration for 48 h. Then, after labeling with
51Cr, equal numbers of target
cells (1310
5/ml) were incubated with serial dilutions of rituximab (from 2.5 to 0.0005 lg/ml) and effector peripheral blood mononuclear cells at E:T¼
100:1 for 4 h. *p , 0.001 (two-way Student’s t-test) as compared with controls.
doi:10.1371/journal.pmed.0050064.g001
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Statins Impair Antitumor Effects of RituximabFigure 2. The Influence of Lovastatin on the Expression of CD20 in Raji Cells
(A) Raji cells were incubated with either diluent (line indicating 0 lM) or lovastatin (1–20 lM) for 48 h. Then, 1 3 10
6/ml of cells were incubated with
saturating amounts of FITC-conjugated anti-CD20 mAb (B9E9) or IgG1 (isotype control) for 30 min at room temperature in the dark. Binding of mAb to
Raji cells was measured with flow cytometry.
(B) CD20 mRNA levels in Raji cells incubated with either diluent (controls) or 10 lM lovastatin for 1 to 48 h assayed by RT-PCR.
(C) CD20 protein levels in Raji cells incubated with either diluent or 5, 10, 20, and 30 lM lovastatin for 48 h and assayed by Western blotting (NCL-CD20-
L26 mAb).
(D–G) Raji cells were incubated with either diluent (ctrl) or 10 lM lovastatin for 48 h. Then, 1310
6/ml of cells were incubated with saturating amounts
of PE-conjugated anti-CD19 mAb (D), PE-conjugated anti-CD22 mAb (E), FITC-conjugated anti-HLA-DR mAb (F), FITC-conjugated anti-CD45RA mAb (G),
or IgG1 (isotypic control) for 30 min at room temperature in the dark. Binding of mAb to Raji cells was measured with flow cytometry.
(H) Immunofluorescence studies of Raji cells incubated for 48 h with either diluent or 10 lM lovastatin. Raji cells were incubated with FITC-conjugated
(green) mAb (B9E9) to detect the extracellular (conformational) epitope located in the larger CD20 loop. Upon washing with PBS, the cells were
permeablized with acetone and incubated with IgG1 mAb (NCL-CD20-L26) directed against a cytoplasmic (linear) epitope within CD20 molecule. After
washing, a secondary Alexa555-labeled (red) anti-IgG1 (anti–NCL-CD20-L26) mAb was used. Bar ¼ 50 lm.
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Statins Impair Antitumor Effects of Rituximabof the ﬁrst peak in a histogram obtained to the unbinding
event of a single molecular complex [34]. Here, it is assumed
that the unbinding probability is lower than 30% and that
only a few molecular bonds are expected to have formed.
Figure 7B presents the unbinding force calculated on the
basis of these force histograms. The unbinding force
calculated for a single antibody–antigen complex determined
in the control experiment was larger (38.8 6 1.3 pN) than
after lovastatin treatment (32.9 6 1.7 pN) and after blocking
available binding sites with soluble rituximab (31.4 6 2.0 pN).
Limited proteolysis of the surface proteins by T and ChT is
another indirect method for determining conformational
changes [35]. Control and lovastatin-pretreated Raji cells
were incubated with increasing concentrations of T and ChT.
Total cellular lysates were then separated in SDS-PAGE and
probed with anti-CD20 mAb detecting an intracellular part of
CD20 antigen. In control cells, incubations with 15 lg/ml ChT
resulted in digestion of CD20 protein (a lower band appears
in Figure 7C); at higher concentrations, the intensity of the
lower band increases. In contrast, in lovastatin-pretreated
cells, CD20 is not digested even by the highest ChT
concentration (Figure 7D). The susceptibility to T digestion
of control and lovastatin-pretreated cells seems to be similar,
although there are some important differences. Similarly to
ChT digestion, lovastatin-pretreated cells seem to be less
susceptible to T treatment. The upper band (representing
undigested protein) disappears in samples of control cells
treated with 20 and 25 lg/ml of the enzyme, while it is still
present in samples of lovastatin-pretreated cells. We excluded
the possibility that lovastatin inhibits ChT and T activity by
performing the limited proteolysis of control cells in the
presence of both proteases and 10 lM lovastatin (unpublished
data). Altogether, it seems that the observed cholesterol-
dependent effects are due to conformational changes in
CD20 antigen, affecting the binding of type I and type II anti-
CD20 antibodies.
Cholesterol Depletion Impairs Anti-CD20 Binding and
Rituximab-Mediated CDC of Freshly Isolated Human B Cell
Lymphoma Cells
To further investigate the effect of cholesterol depletion on
immunotherapy, we studied whether MbCD treatment
reduced the capacity of rituximab to lyse freshly isolated
cells of patients with B cell lymphoma. In all four patients
with B cell lymphoma studied (three with mantle cell
lymphoma and one with small B cell lymphoma), we observed
that a 30-min incubation of lymphoma cells with 10 mg/ml
MbCD signiﬁcantly decreased binding of anti-CD20 (B9E9)
mAb, while binding of anti-CD19 mAb was affected to a lesser
extent (Figure 8). Accordingly, incubation with MbCD
(I) Higher magnification of Raji cells stained with both extracellular and intracellular epitopes (two different areas are shown for each group). Bar¼10
lm.
(J) Control or lovastatin-treated (10 lM for 48 h) Raji cells (1310
6) were incubated with EZ-link sulfo-NHS-biotin. Total cellular lysates were precipitated
with immobilized NeutrAvidin protein followed by electrophoresis and blotting with anti-CD20 (NCL-CD20-L26 mAb) and anti–ICAM-1 mAb.
doi:10.1371/journal.pmed.0050064.g002
Figure 3. The Influence of Cholesterol-Modulating Drugs on the Expression of CD20 in Raji Cells
(A–C) Raji cells were incubated with either diluents or MbCD (0–10 mg/ml) for 30 min, filipin III (0–1 lg/ml) for 30 min, or berberine (0–30 lg/ml) for 24
h. Then, equal numbers of cells (1 3 10
5/well) were incubated for 60 min with 10 lg/ml rituximab in the presence of 10% human AB serum as a
complement source. Cell viability was measured in a MTT assay.
(D–F) Raji cells were incubated with either diluents or MbCD (5 mg/ml) for 30 min, filipin III (0.5 lg/ml) for 30 min, or berberine (25 lg/ml) for 24 h. Then,
1 3 10
6/ml cells were incubated with saturating amounts of FITC-conjugated anti-CD20 mAb (B9E9) or IgG1 (isotype control) for 30 min at room
temperature in the dark. Control indicates the cells not incubated with MbCD, filipin III, and berberine, respectively. *p , 0.001 (two-way Student’s t-
test) as compared with controls. Binding of mAb to Raji cells was measured with flow cytometry.
doi:10.1371/journal.pmed.0050064.g003
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Statins Impair Antitumor Effects of Rituximabsigniﬁcantly decreased rituximab-mediated CDC of B cell
lymphoma cells (Figure 8).
Short-Term Statin Treatment Reduces Binding of Anti-
CD20 mAb to the Surface of Peripheral Blood B Cells in
Patients
To extend our observations, we studied the inﬂuence of
cholesterol depletion on freshly isolated B cells from patients
originally diagnosed with hypercholesterolemia who were
treated with atorvastatin. A small exploratory clinical study
was performed in which ﬁve patients were treated with a daily
dose of 80 mg atorvastatin in order to reduce their
cholesterol blood level and to determine the effect on anti-
CD20 mAb binding on freshly isolated B cells using ﬂow
cytometry with anti-CD20 mAbs and a PE-conjugated anti-
CD21 mAb. CD21 is an antigen expressed on B cells that was
unaffected by cholesterol depletion on both B cell lines
(Daudi and Raji) and freshly isolated B cell–enriched cell
populations of three independent donors (unpublished data).
Therefore, anti-CD21 mAb binding was considered to be an
indicator for the amount of B cells present per staining. The
ratio of MFI of CD20/CD21 mAb staining was calculated and
served as a relative measure for CD20 expression. Figure 9A
shows that atorvastatin treatment led to a signiﬁcant
reduction in blood cholesterol levels in all ﬁve patients (the
average reduction in blood cholesterol level was 17.5% 6
3.6%; p , 0.01, Student’s t-test). Freshly isolated B cells of
patients stained with FITC-conjugated anti-CD20 mAb
(ofatumumab) showed a decrease of 18.2% 6 3.5% (p ¼
0.01, Student’s t-test) in binding for all ﬁve patients when
compared with day 0 (pretreatment; Figure 9B). Similarly,
staining with FITC-conjugated anti-CD20 mAb B1 resulted in
a decreased CD20/CD21 MFI ratio for three out of ﬁve
patients (unpublished data). Our results suggest that short-
term statin usage lowers anti-CD20 mAb binding to B cells.
Discussion
We observed that statins can indirectly affect conformation
of CD20 molecules expressed on the surface of normal and
malignant B lymphocytes. Conformational changes in CD20
molecules impair their recognition by mAbs, thereby com-
promising rituximab-mediated CDC and ADCC against
lymphoma cells. CD20 is an integral membrane protein with
tetraspanning topology, in which both the C and N termini
are located within the cell [36]. It is predicted to have two
extracellular loops: a very small loop between the ﬁrst and
second transmembrane regions, and a larger loop of
approximately 44 extracellular amino acids located between
the third and fourth transmembrane regions [36]. Most anti-
CD20 mAbs, including the rituximab, B1, and B9E9 studied in
this work, recognize overlapping epitopes within the larger
loop [33]. Mutagenesis studies revealed that the region
surrounding alanine 170 (A170) and proline 172 (P172) is
essential for rituximab binding [37]. A recent report revealed
that rituximab binds a discontinuous epitope in CD20
comprising four amino acids between A170 and S173 and
ﬁve amino acids between Y182 and I186 [38]. Two amino
acids in this region, C167 and C183, form a disulﬁde bond
that appears critical for rituximab binding to maintain
appropriate conformation of the epitope [38]. Initial studies
indicated that CD20 density is a critical factor for rituximab-
Figure 4. The Influence of Statins, FTI, and GGTI Inhibitors and siRNA on
Antibody-Mediated CDC and/or CD20 Detection
Raji cells were incubated with either diluent or 1 lM cerivastatin (A), 10
lM fluvastatin (B), or 10 lM atorvastatin (C) for 48 h. Then, 1310
6/ml of
cells were incubated with saturating amounts of FITC-conjugated anti-
CD20 mAb (B9E9) or IgG1 (isotypic control) for 30 min at room
temperature in the dark. Binding of mAb to Raji cells was measured with
flow cytometry.
(D) Raji cells were transfected with siRNA targeting HMG-CoAR or
irrelevant siRNA using OligofectAMINE. After 48 h, 1 3 10
6/ml of cells
were labeled as described above.
(E) Daudi cells were incubated with either diluent or 10 mg/ml MbCD for
30 min. Then, 1 3 10
5/ml of cells were incubated with saturating
amounts of the FITC-conjugated anti-CD20 mAbs ofatumumab, ritux-
imab, B1, and B9E9 for 30 min at room temperature in the dark. The MFI
corrected for the FITC–protein ratio was measured with flow cytometry.
(F) Ramos cells were incubated with either diluent or lovastatin (10 and
50 lM) for 48 h. Then, equal numbers of cells (1 3 10
5/well) were
incubated for 60 min with 10 lg/ml alemtuzumab in the presence of
10% human AB serum as a complement source. Cell viability was
measured in a MTT assay. The survival of cells is presented as percentage
of corresponding diluent- or statin-pretreated cells without alemtuzu-
mab.
doi:10.1371/journal.pmed.0050064.g004
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Statins Impair Antitumor Effects of Rituximabmediated CDC. However, it was recently shown by Teeling et
al. that the binding characteristics and ﬁne speciﬁcity of anti-
CD20 mAbs also have a major inﬂuence on their ability to
mediate CDC [33]. The ﬁne speciﬁcity of mAbs recognizing a
conformational epitope relies heavily on the target antigen’s
3-D structure, which may be modulated by the plasma
membrane. Disrupting the membrane of non-Hodgkin
lymphoma (NHL) cells with detergents such as Triton X-100
results in loss of binding of anti-CD20 mAbs, again indicating
that the topography of CD20 in the lipid bilayer is critical to
epitope structure [33]. Altogether, accumulating evidence
indicates that the ability of mAbs to interact with CD20 is
dependent on both the expression level as well as steric
restrictions imposed by its conformation in the plasma
membrane. Our studies indicate that plasma membrane
cholesterol is necessary for the maintenance of a CD20
conformational state that supports rituximab binding. By
depleting cholesterol through inhibition of its synthesis with
statins and berberine or through its direct removal with
MbCD, we observed a signiﬁcant reduction of rituximab-
mediated CDC as well as binding of B9E9 to an extracellular
loop of CD20. Cholesterol restitution experiments revealed
even stronger rituximab-mediated CDC than in controls
despite incomplete reversal of anti-CD20 staining. Exogenous
cholesterol might play a dual role in this experimental
setting: it might not only restore the conformation of CD20
(Figure 6), but also facilitate formation and penetration of the
membrane attack complex into the plasma membrane.
Similarly, erythrocytes for example have been shown to
become more susceptible to lysis at increased cholesterol
content [39].
The effect of statins did not result from shedding of CD20
from plasma membrane as has been shown for some other
molecules. For example, CD30 was reported to localize to
lipid rafts; after disruption with statins, MbCD, or ﬁlipin III,
this molecule became exposed to membrane metallopro-
Figure 5. Correlation Between Reduced Anti-CD20 mAb Binding and Decreased Rituximab-Mediated CDC in Lovastatin-Treated Cells
Raji (A), Ramos (B), or Daudi (C) cells were incubated with either diluent or lovastatin (10 lM) for 48 h. Then, equal numbers of cells (1310
5/well) were
incubated for 60 min with 10 lg/ml rituximab in the presence of 10% human AB serum as a complement source. Cell viability was measured in a MTT
assay. The survival of cells is presented as percentage of corresponding diluent- or statin-pretreated cells without rituximab (left graphs). Raji, Ramos,
and Daudi cells were incubated with either diluent or lovastatin (10 lM) for 48 h. Then, 1 3 10
6/ml of cells were labeled with FITC-conjugated B9E9
(center graphs) or rituximab (right graphs) and a secondary FITC-conjugated anti-IgG1 antibody. *p , 0.001 (two-way Student’s t-test) as compared
with controls.
doi:10.1371/journal.pmed.0050064.g005
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Statins Impair Antitumor Effects of Rituximabteases that generated soluble CD30 [40]. First, CD20 is
recruited to lipid rafts only after anti-CD20 mAb binding,
so it is unlikely that it is shielded from membrane metal-
loproteases [20,22]. Moreover, we could not restore binding
of mAb to CD20 after co-incubation of Raji cells with
lovastatin and phenantroline, a broad-speciﬁcity metallopro-
tease inhibitor (unpublished data). Restitution experiments
revealed that a short 30-min incubation of Raji cells with
exogenous cholesterol almost completely restores B9E9
binding as well as rituximab-mediated CDC in lovastatin-
pretreated cells. Finally, immunoﬂuorescence microscopy,
labeling of extracellular proteins with sulfo-NHS-biotin,
AFM, and the observation that maximal rituximab binding
levels in ﬂow cytometry are approximated at high antibody
concentration clearly showed that CD20 is still present in
plasma membrane of lovastatin-treated cells in levels com-
parable with that of untreated controls.
It can be argued that statins might also impair rituximab-
mediated CDC by increasing the expression of complement-
inhibitory proteins, including CD55 and CD59 [41,42].
However, this mechanism is unlikely to be responsible for
statin-induced impairment of rituximab-mediated CDC, as
we have not observed any induction of these proteins in Raji
cells by Western blotting or ﬂow cytometry (unpublished
data).
Our knowledge on the inﬂuence of membrane cholesterol
on the 3-D conformation of transmembrane proteins is
rather limited. Cholesterol modulates the ﬂuidity of bio-
logical membranes by inserting between fatty acid acyl chains,
thereby abolishing phase transitions of bilayers [43]. There-
fore, it is intuitive that the amount of membrane cholesterol
might indirectly affect biophysical interactions between
membrane lipids and proteins, especially in those that cross
the plasma membrane several times. For example, MbCD-
mediated cholesterol depletion from plasma membrane
decreased the afﬁnity of oxytocin to its receptor [44].
Cholesterol was also demonstrated to modulate the function
of the cholecystokinin receptor through changes in mem-
brane ﬂuidity. Both receptors are G-protein coupled with
seven transmembrane regions. Cholesterol in the endoplas-
mic reticulum causes conformational changes in SCAP, a
polytopic endoplasmic reticulum membrane protein that
cleaves sterol regulatory element binding proteins (SREBPs)
[45]. Moreover, cholesterol depletion with MbCD was shown
to interfere with antigen binding of the anti-CD20 mAb
FMC7 [46] as well as several other CD20 mAbs [21].
We have observed that incubation of Raji cells with
lovastatin renders CD20 resistant to ChT-limited proteolysis,
thereby indicating that some critical ChT-sensitive residues
become unavailable for digestion (Figure 7C and 7D).
Moreover, AFM studies revealed that lovastatin-treated cells
still express CD20, but the afﬁnity (binding force) of
rituximab is decreased, indicating potential conformational
changes (Figure 7B). Also, a subtle difference in CD20
precipitation with sulfo-NHS-biotin (Figure 2J) might be
caused by conformational changes in CD20, resulting in steric
hindrance of some amino groups for biotinylation. Alto-
gether, the data presented here indicate that statins appear to
affect a cholesterol-dependent conformation of CD20, there-
by impairing mAb binding, CDC, and ADCC of CD20-
expressing lymphoma cells.
Critical issues for the clinical translation of our studies are
the statin concentrations and accompanying changes in
cholesterol levels achievable in patients. Serum statin con-
centrations in patients with hypercholesterolemia have been
shown to be in sub-micromolar range. Nonetheless, in a
recent study of lovastatin administered to patients with
advanced cancers, serum lovastatin concentrations reached
12 lM [47]. In most of our studies we have used lovastatin and
other statins at 10 lM concentration. At lower concentrations
(2.5–5.0 lM), lovastatin also decreased rituximab-mediated
CDC, indicating that the observed effects might be clinically
relevant. Our in vitro studies, however, may not accurately
Figure 6. Cholesterol Is Necessary for CD20 Binding and Rituximab-
Mediated CDC
Raji cells were incubated with either diluent or lovastatin (10 lM for 48 h
[A and B]), simvastatin (10 lM for 48 h [C and D]) or MbCD (5 mg/ml for
30 min [E and F]). Water-soluble cholesterol (chol; 0.2 mg/ml) was added
for 2 h prior to flow cytometry analysis (A, E) or addition of 10 lg/ml
rituximab and 10% human AB serum (B and F). Mevalonic acid (MA) was
added together with simvastatin at a 200 lM concentration (C and D).
Then for flow cytometry studies (A, C, and E), 1 3 10
6/ml of cells were
incubated with saturating amounts of FITC-conjugated anti-CD20 mAb
(B9E9) or IgG1 (isotype control) for 30 min at room temperature in the
dark. Cell viability was measured in a MTT assay (B, D, and F). The survival
of cells is presented as percentage of corresponding diluent- or statin-
pretreated cells without rituximab. *p , 0.001 (two-way Student’s t-test)
as compared to statin-treated (B and D) or MbCD-treated (F) cells.
doi:10.1371/journal.pmed.0050064.g006
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Statins Impair Antitumor Effects of Rituximabreﬂect the clinical situation. Even though Raji cells were
incubated with statins for only 48 h, and patients are taking
cholesterol-reducing drugs on a regular basis for extended
periods of time, it is quite possible that cholesterol is depleted
more strongly in vitro than in vivo. Therefore, a small
exploratory clinical study of patients with hypercholester-
olemia was designed to test the hypothesis that in vivo
changes in plasma cholesterol inﬂuence the binding of anti-
CD20 antibodies to CD20-expressing cells. We observed that
even a short-term atorvastatin treatment leads to a statisti-
cally signiﬁcant reduction in anti-CD20 mAb binding, which
roughly parallels the reduction in plasma cholesterol. The full
impact of plasma cholesterol changes due to statin treatment
(or other clinical, environmental, or genetic causes) on
immunotherapy with rituximab and other anti-CD20 anti-
bodies should be studied in clinical trials in which patients
are stratiﬁed on basis of their plasma cholesterol content and/
or statin usage.
Figure 7. Lovastatin Changes Conformation of CD20 in Raji Cells
(A) The force curve obtained for the interaction between rituximab attached to the AFM tip and the antigen (CD20) present on the surface of living cells
is shown. The unbinding force Funb was determined as a difference between the base line and the force value Fmin at the moment of bond rupture.
(B) The unbinding force calculated for the interaction between the mAb-coated AFM tip and the antigen (CD20) on cell surface was assessed in a
control measurement, lovastatin treatment, and after blocking of the antigen binding sites by soluble rituximab, respectively. The estimated errori sa
standard deviation of the mean (SEM). Control (C) and lovastatin-pretreated (D) Raji cells were treated with increasing concentrations of trypsin and
chymotrypsin. Cell lysates were separated in SDS-PAGE and probed with anti-CD20 (NCL-CD20-L26 mAb) detecting the intracellular part of CD20
antigen.
doi:10.1371/journal.pmed.0050064.g007
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Statins Impair Antitumor Effects of RituximabThe changes in cholesterol levels on CD20 epitope
exposure, as demonstrated in the current study, have
important clinical implications. It is possible that statins
and potentially other cholesterol-lowering drugs can affect
diagnosis of lymphoid malignancies, as often determined with
antibody-based reagents on blood cells in ﬂow cytometry.
Fluctuations in plasma cholesterol may furthermore affect
anti-CD20 therapy by decreasing activity under low-choles-
terol conditions but increasing activity at high cholesterol.
Consistency of anti-CD20 therapy might therefore beneﬁt
Figure 8. The Influence of MbCD on the Expression of CD19 and CD20 As Well As on Rituximab-Mediated CDC Against Primary Human Lymphoma Cells
Primary human CD20
þ B cell lymphoma cells—mantle cell lymphomas in (A–C), and small B cell lymphoma in (D)—were incubated with either diluent
or MbCD (10 mg/ml) for 30 min. Then, 1310
6 cells/ml were incubated with saturating amounts of FITC-conjugated anti-CD20 mAb (B9E9, left graphs),
PE-conjugated anti-CD19 mAb (center graphs), or IgG1 (isotype control) for 30 min at room temperature in the dark. For the rituximab-mediated CDC,
human CD20
þB cell lymphoma cells were incubated with either diluent or 10 mg/ml MbCD for 30 min. Then, equal numbers of cells (1310
5/well) were
incubated for 60 min with 400 lg/ml rituximab in the presence of 10% human AB serum as a complement source. Cell viability was measured in a MTT
assay. The survival of cells is presented as percentage of corresponding diluent- or MbCD-pretreated cells without rituximab (right graphs). *p¼0.032
for (A), p , 0.001 for (B) and (C), and p ¼ 0.041 for (D) (two-way Student’s t-test) as compared with controls.
doi:10.1371/journal.pmed.0050064.g008
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Statins Impair Antitumor Effects of Rituximabfrom the application of antibodies that are less sensitive to
such changes and/or efﬁciently lyse cells at low antibody
occupancy or low CD20 expression levels.
In summary, our study shows that changes in membrane
cholesterol affect CD20 antibody binding in vitro and in vivo.
The inﬂuence of statin treatment and plasma cholesterol on
CD20 immunotherapy should be addressed in clinical studies
with CD20 antibodies currently ongoing in oncology as well
as in inﬂammatory diseases.
Supporting Information
Alternative Language Abstract S1. Translation of the Abstract into
Polish
Translated by Jakub Golab.
Found at doi:10.1371/journal.pmed.0050064.sd001 (27 KB DOC).
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Editors’ Summary
Background. Lymphomas are common cancers of the lymphatic system,
the tissues and organs that produce and store the white blood cells
(lymphocytes) that fight infections. In healthy people, the cells in the
lymph nodes (collections of lymphocytes in the armpit, groin, and neck)
and other lymphatic organs divide to form new cells only when the body
needs them. Lymphomas form when a T or B lymphocyte starts to divide
uncontrollably. The first sign of lymphoma is often a painless swelling in
the armpit, groin, or neck caused by lymphocyte overgrowth in a lymph
node. Eventually, the abnormal (malignant) lymphocytes, which provide
no protection against infectious diseases, spread throughout the body.
Treatments for lymphoma include chemotherapy (drugs that kill rapidly
dividing cells) and radiotherapy. In addition, a drug called rituximab was
recently developed for the treatment of some types of B cell lymphoma.
Rituximab is a monoclonal antibody, a laboratory-produced protein. It
binds to a protein called CD20 that is present on the surface of both
normal and malignant B lymphocytes and induces cell killing through
processes called ‘‘complement-dependent cytotoxity’’ (CDC) and ‘‘anti-
body-dependent cellular cytotoxity’’ (ADCC).
Why Was This Study Done? Although rituximab lengthens the lives of
patients with some types of B cell lymphoma, it is not a cure—the
lymphoma usually recurs. Researchers are trying to increase the
effectiveness of rituximab by combining it with other anticancer agents.
One group of drugs that might be combined with rituximab is the
‘‘statins,’’ drugs that reduce the risk of heart disease by lowering the
level of cholesterol (a type of fat) in the blood. In laboratory experiments,
statins kill some cancer cells, in part by altering the fat composition of
their outer (plasma) membrane. In addition, some population-based
studies suggest that statin treatment might slightly decrease the risk of
developing some kinds of cancer, including lymphoma. Statins are
already undergoing clinical evaluation in combination with chemo-
therapy for the treatment of lymphoma, but in this study, the researchers
investigate the influence of statins on rituximab-induced killing of B cell
lymphomas.
What Did the Researchers Do and Find? When the researchers tested
the ability of rituximab and statin combinations to kill B cell lymphoma
cells growing in dishes, they found that statins decreased rituximab-
dependent CDC and ADCC of these cells. Statin treatment, they report,
did not alter the total amount of CD20 made by the lymphoma cells or
the amount of CD20 in their plasma membranes, but it did reduce the
binding of another anti-CDC20 monoclonal antibody to the cells.
Because both this antibody and rituximab bind to a specific three-
dimensional structure in CD20 (a ‘‘conformational epitope’’), the
researchers hypothesized that statins might alter rituximab-induced
killing by affecting the shape of the CD20 molecule on the lymphoma
cell surface. To test this idea, they used two techniques—atomic force
microscopy and limited proteolysis. The data obtained using both
approaches confirmed that statins induce shape changes in CD20.
Finally, the researchers took B cells from five patients who had taken
statins for a short time and showed that this treatment had reduced the
amount of anti-CD20 monoclonal antibody able to bind to these cells.
What Do These Findings Mean? These findings indicate that statins
change the shape of the CD20 molecules on the surface of normal and
malignant B lymphocytes, probably by changing the amount of
cholesterol in the cell membrane. This effect of statins has several
clinical implications, which means that cancer specialists should check
whether patients with known or suspected B cell lymphoma are taking
statins to treat high cholesterol. First, the impaired binding of
monoclonal antibodies to conformational epitopes of CD20 in patients
being treated with statins might delay the diagnosis of B cell lymphomas
(CD20 binding to lymphocytes is used during the diagnosis of
lymphomas). Second, some patients with B cell lymphoma may receive
an incorrect diagnosis and may not be offered rituximab. Finally, because
statins impair the anti-lymphoma activity of rituximab, a possibility that
needs to be investigated in clinical studies, cancer specialists should
check that patients with B cell lymphoma are not taking statins before
prescribing rituximab.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050064.
  The MedlinePlus has an encyclopedia page on lymphoma and a list of
links to other sources of information on lymphoma (in English and
Spanish)
  The US National Cancer Institute provides information about
lymphoma and about statins and cancer prevention (in English and
Spanish)
  The UK charity Cancerbackup provides information for patients and
caregivers on different types of B-cell lymphoma and on rituximab
  The US Leukemia and Lymphoma Society also provides information for
patients and caregivers about lymphoma
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